Lv1
50 积分 2024-05-28 加入
The Adjuvant MF59: A 10-Year Perspective
8小时前
待确认
Vaccine Technology: Adjuvants for Increased Efficacy
7天前
已完结
Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines
18天前
已完结
Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial
5个月前
已完结
Effect of early versus late or no tracheostomy on mortality and pneumonia of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis
6个月前
已完结
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial
6个月前
已完结
Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice
6个月前
已完结
Formulation of Recombinant H1N1 Hemagglutinin in MF59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in BALB/C Mice
6个月前
已完结
Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
6个月前
已完结
Harmonization of viral vector quantification: A consensus guideline from the International Consortium on Virological Metrics (ICVM)
7个月前
已关闭
皖公网安备34019202002308
